Clinical trial · Observational
Interplay Between Immune and Metabolic Programs in Myelodysplastic Syndromes
Interplay Between Immune and Metabolic Programs in Myelodysplastic Syndromes: Involvement in Leukemia Transformation and Therapeutic Targeting
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Myelodysplastic syndromes (MDS) are a pre-leukemic condition with an extremely poor prognosis despite current treatments that justify new therapeutic approaches. Various studies have described the potential involvement of both immune compartment and cellular metabolism in the pathophysiology of MDS. The aim of this study is to determine the specific immune and metabolic profiles of the different classes of MDS and to identify predictive markers of progression/survival/response to therapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Myelodysplastic Syndromes | Myelodysplastic Syndrome | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (2)
- label
- Patient with a myelodysplastic syndrome
- description
- Patient over 18 years of age with a myelodysplastic syndrome (WHO 2016 classification) of low risk (LR= International Prognostic Scoring System (IPSS)-R\<4.5) or high risk (HR=Revised International Prognostic Scoring System\>4.5)
- label
- Control patient
- description
- Healthy blood donor (regardless of age) Or Patient \>60 years old, see at the geriatrics platform of the hospital la Grave (CHU of Toulouse), having expressed his non opposition to participate in the study
Primary outcomes (1)
- measure
- Immune and metabolic profiles will be evaluated by immunophenotyping
- timeFrame
- Day 0
- description
- phenotypic study of one or more leukocyte sub-populations by flow cytometry
Secondary outcomes (1)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 99 Years
Show eligibility criteria text
Inclusion Criteria: * Patients: * Patient over 18 years of age with a myelodysplastic syndrome (WHO 2016 classification) of low risk (LR=IPSS-R\<4.5) or high risk (HR=IPSS-R\>4.5); * Patient naïve to specific treatment of MDS; * Patient who expressed no opposition to participating in the study. ; * Patient affiliated with the social security system. * Control: * over 18 years of age, * Sample from blood donation (regardless of age) Or Patient \>60 years old, see at the geriatrics platform of the hospital la Grave (CHU of Toulouse), * having expressed his non opposition to participate in the study Exclusion Criteria: * Patients: * Myeloid disease other than MDS (including chronic myelomonocytic leukemia and MDS/SMP) ; * Ongoing treatments for MDS (excluding erythropoietin, granulocyte colony-stimulating factor and transfusions) ; * Medical conditions that may interfere with immune system testing: active cancer, active autoimmune disease, inflammatory conditions, immunosuppressive therapy. ; \* Pregnant or breastfeeding women ; Patient's refusal ; * Person benefiting from a system of protection for adults (including guardianship, curators and safeguarding of justice) * Control: * Medical conditions that may interfere with immune system testing: active cancer, active autoimmune disease, inflammatory conditions, immunosuppressive therapy. ; \* Pregnant or breastfeeding women ; * Patient's refusal ; * Person benefiting from a system of protection for adults (including guardianship, curators and safeguarding of justice)
References
Publications (0)
Data not yet available